|Bid||67.30 x 100|
|Ask||99.98 x 300|
|Day's Range||88.88 - 90.62|
|52 Week Range||80.10 - 100.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
BioMarin's Jean-Jacques Bienaime believes the company's hemophilia treatment could fundamentally change the quality of life for patients.
The JPMorgan Healthcare Conference, one of the biggest and most important events of the year for biotech investors, kicks off this week. Last week, Morgan Stanley analyst Matthew Harrison compiled a report ...
BioMarin Pharmaceutical (BMRN) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.
BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.
Presentations on potentially game-changing gene therapies were front and center at this year's American Society of Hematology conference.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) shares have been having a stellar run following its presentation at the American Society of Hematology's annual meeting. Notwithstanding the rally, one analyst ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioMarin Pharmaceutical, Inc. a score of 47. Our analysis is based on comparing BioMarin Pharmaceutical, Inc. with the following peers – Ultragenyx Pharmaceutical, Inc., Shire PLC Sponsored ADR, Esperion Therapeutics, Inc., Sanofi Sponsored ADR, Sangamo Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. ... Read more (Read more...)
The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was ...
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Shares of Spark Therapeutics’ (ONCE) are down on Tuesday, continuing their decline from Monday, when it reported disappointing data that lagged rival BioMarin(BRMN). Leerink's Joseph Schwartz and Dae ...